Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$43.97 USD

43.97
735,574

+0.74 (1.71%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings

Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.

Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?

In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.

Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?

Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi

Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes

Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).

Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.

Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?

Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Tandem Diabetes Care (TNDM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 4.85% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline

Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?

Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).

Tandem Diabetes Care, Inc. (TNDM) Surges 9.6%: Is This an Indication of Further Gains?

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -17.39% and 3.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi

Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.